Ultragenyx Pharmaceutical Inc.
- Jurisdiction
United States - LEI
529900EV44GVDN1DCX77 - ISIN
US90400D1081 (RARE )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Read full profile
Fundamentals
- Net revenue
€520.44M - Gross margin
83.9% - EBIT
-€430.82M - EBIT margin
-82.8% - Net income
-€454.56M - Net margin
-87.3%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Huizenga Theodore Alan | SVP, Chief Accounting Officer |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Gilbert Cisneros | September 12, 2025 | $1.00K–$15.00K |
| Gilbert Cisneros | August 14, 2025 | $1.00K–$15.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |